BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 16640847)

  • 1. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America.
    Tregnaghi M; López P; Rocha C; Rivera L; David MP; Rüttimann R; Schuerman L
    Rev Panam Salud Publica; 2006 Mar; 19(3):179-88. PubMed ID: 16640847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine in Costa Rican children who had received a birth dose of hepatitis B vaccine.
    Faingezicht I; Avila-Aguerro ML; Cervantes Y; Fourneau M; Clemens SA
    Rev Panam Salud Publica; 2002 Oct; 12(4):247-57. PubMed ID: 12431356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new DTPw-HBV/Hib vaccine: immune memory after primary vaccination and booster dosing in the second year of life.
    Gatchalian S; Reyes M; Bermal N; Chandrasekaran V; Han HH; Bock HL; Lefevre I
    Hum Vaccin; 2008; 4(1):60-6. PubMed ID: 18376148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and booster vaccination in Latin American children with a DTPw-HBV/Hib combination: a randomized controlled trial.
    Espinoza F; Tregnaghi M; Gentile A; Abarca K; Casellas J; Collard A; Lefevre I; Jacquet JM
    BMC Infect Dis; 2010 Oct; 10():297. PubMed ID: 20950456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth.
    Gatchalian S; Reyes M; Bernal N; Lefevre I; David MP; Han HH; Bock HL; Wolter J; Schuerman L
    Hum Vaccin; 2005; 1(5):198-203. PubMed ID: 17012860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children.
    Santos JI; Martin A; De Leon T; Rivera L; Gaitán ME; Del Rio C; Oselka G; Cervantes Y; Rubio P; Clemens SA; de Mendonça JS
    Vaccine; 2002 Mar; 20(13-14):1887-93. PubMed ID: 11906779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
    Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
    Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4 and 6 months of age, with a booster at 18 months.
    Riedemann S; Reinhardt G; Jara J; Rios R; Wenzel MS; Willems P; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):215-22. PubMed ID: 12718838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers.
    Quiambao B; Van Der Meeren O; Kolhe D; Gatchalian S
    Hum Vaccin Immunother; 2012 Mar; 8(3):347-54. PubMed ID: 22330958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparate kinetics in immune response of two different
    Martinón-Torres F; Salamanca de la Cueva I; Horn M; Westerholt S; Bosis S; Meyer N; Cheuvart B; Virk N; Jakes RW; Duchenne M; Van den Steen P
    Hum Vaccin Immunother; 2024 Dec; 20(1):2342630. PubMed ID: 38687024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully liquid DTPw-HepB-Hib combination vaccine for booster vaccination of toddlers in El Salvador.
    Suárez E; Asturias EJ; Hilbert AK; Herzog C; Aeberhard U; Spyr C
    Rev Panam Salud Publica; 2010 Feb; 27(2):117-24. PubMed ID: 20339615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents.
    Ortega-Barrìa E; Kanra G; Leroux G; Bravo L; Safary A; Lefevre I;
    Vaccine; 2007 Dec; 25(50):8432-40. PubMed ID: 17961876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.
    Vesikari T; Rivera L; Korhonen T; Ahonen A; Cheuvart B; Hezareh M; Janssens W; Mesaros N
    Hum Vaccin Immunother; 2017 Jul; 13(7):1505-1515. PubMed ID: 28340322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and booster immunization with a diphtheria, tetanus, acellular pertussis, hepatitis B (DTPa-HBV) and Haemophilus influenzae type b (Hib) vaccine administered separately or together is safe and immunogenic.
    Marshall H; McIntyre P; Roberton D; Dinan L; Hardt K
    Int J Infect Dis; 2010 Jan; 14(1):e41-9. PubMed ID: 19467896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a new hexavalent vaccine (DTaP5-IPV-HB-Hib) administered in a mixed primary series schedule with a pentavalent vaccine (DTaP5-IPV-Hib).
    Martinón-Torres F; Boisnard F; Thomas S; Sadorge C; Borrow R;
    Vaccine; 2017 Jun; 35(30):3764-3772. PubMed ID: 28583305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Study of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine for Primary and Booster Vaccinations of Healthy Infants and Toddlers in Latin America.
    López P; Arguedas Mohs A; Abdelnour Vásquez A; Consuelo-Miranda M; Feroldi E; Noriega F; Jordanov E; B Chir S; Zambrano B
    Pediatr Infect Dis J; 2017 Nov; 36(11):e272-e282. PubMed ID: 28719500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.